Peroxisome Proliferator-Activated Receptors (PPARs) Antagonists

Categories: “Other Disorders” “Cancer Therapeutics

Reference #: 2011-004

OTC Contact: Ruchika Nijhara, PhD, MBA, CLP Office: (202) 687-3721 (Directory Information | Send a Message)


The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that regulate glucose, lipid, and cholesterol metabolism in response to fatty acids and their derivatives. The present invention encompasses a new class of small molecules that may serve as antagonists of PPARs.


The novel molecules have potential to be used as therapeutics for diabetes, obesity, metabolic syndrome, impaired glucose tolerance, syndrome X, cancer and cardiovascular disease.


Stage of Development

The inventors have designed and synthesized selective PPAR antagonists and tested their ability to inhibit activation of each PPAR biologically.

Relevant Publications

Manuscript in preparation

Patent Status

Patent protection sought.